Annals of Oncology Advance Access originally published online on December 5, 2006
Annals of Oncology 2007 18(3):561-568; doi:10.1093/annonc/mdl418
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 European Society for Medical Oncology
phase I and pharmacokinetics |
Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors
1 Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland
2 Istituto Nazionale Tumori, Milan, Italy
3 Kantonsspital, St.Gallen, Switzerland
4 Hospital General Vall d'Hebron, Barcelona, Spain
5 SENDO
6 Mario Negri, Milan
7 Casa di Cura Poliambulanza, Brescia
8 Sigma Tau SpA, Rome, Italy
* Correspondence to: Dr L. Gianni, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy. E-mail: luca.gianni{at}istitutotumori.mi.it
Background: Gimatecan is an orally bioavailable camptothecin analogue with preclinical findings of promising antitumor activity. A phase I design of concerted dose escalation and dosing duration was implemented to assess the potential schedule dependency of tolerability that emerged from animal studies.
Patients and methods: Gimatecan was given daily for five consecutive days per week for 1, 2 or 3 weeks every 28 days. Plasma levels of total gimatecan were measured on the first and the last day of treatment in each schedule.
Results: Overall, 108 patients were treated with 0.8–7.2 mg/m2 of gimatecan per cycle. The main toxicity was myelosuppression with dose-limiting thrombocytopenia. In the 1-, 2- and 3-week schedule, the maximum tolerated doses were 4.5, 5.6 and 6.4 mg/m2. Diarrhea and asthenia were of low grade and of minor clinical relevance, while the higher incidence of nausea and vomiting in the 1-week schedule required the use of antiemetic prophylaxis. Due to the prolonged half-life (
77 h), the plasma concentration of gimatecan increased from the first to the last day of dosing. Six partial responses were observed.
Conclusions: Tolerability of gimatecan was schedule dependent. Further testing with schedules taking into account its long persistence in human plasma is worthwhile.
Key words: concerted dose escalation, gimatecan, oral camptothecin, pharmacokinetics, phase I
Received for publication June 13, 2006. Revision received September 4, 2006. Accepted for publication September 22, 2006.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. M. Arnold, J. J. Rinehart, E. Tsakalozou, J. R. Eckardt, S. Z. Fields, B. J. Shelton, P. A. DeSimone, B. K. Kee, J. A. Moscow, and M. Leggas A Phase I Study of 7-t-Butyldimethylsilyl-10-Hydroxycamptothecin in Adult Patients with Refractory or Metastatic Solid Malignancies Clin. Cancer Res., January 15, 2010; 16(2): 673 - 680. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Pecorelli, I. Ray-Coquard, O. Tredan, N. Colombo, G. Parma, G. Tisi, D. Katsaros, C. Lhomme, A. A. Lissoni, J. B. Vermorken, et al. Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes Ann. Onc., November 11, 2009; (2009) mdp514v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. X. Zhu, N. Ready, J. W. Clark, H. Safran, A. Amato, N. Salem, S. Pace, X. He, N. Zvereva, T. J. Lynch, et al. Phase I and Pharmacokinetic Study of Gimatecan Given Orally Once a Week for 3 of 4 Weeks in Patients with Advanced Solid Tumors Clin. Cancer Res., January 1, 2009; 15(1): 374 - 381. [Abstract] [Full Text] [PDF]
|
|